Dow Jones
38 460,92 -42,77 (-0,11 %) Nasdaq
15 712,75 +16,11 (+0,10 %) Nikkei 225
37 818,11 -641,97 (-1,67 %) EUR/USD
1,0709 +0,0008 (+0,07 %) HANG SENG
17 318,61 +117,34 (+0,68 %) Bitcoin EUR
60 183,12 -2 105,48 (-3,38 %)
Teva Pharmaceutical Industries Limited (TEVA)
Échanges après Bourse :
Teva Pharmaceutical Industries Limited
124 Dvora HaNevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 35 001
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Richard D. Francis | President, CEO & Director | 6,71M | S.O. | 1968 |
| Mr. Eliyahu Sharon Kalif | Executive VP & CFO | 1,94M | S.O. | 1974 |
| Mr. Eric Drape | Executive Vice President of Global Operations | 2,25M | S.O. | 1962 |
| Mr. Mark Sabag | Executive Vice President of International Markets Commercial | 1,73M | S.O. | 1971 |
| Mr. Richard Gordon Daniell | Executive Vice President of European Commercial | 1,66M | S.O. | 1967 |
| Mr. Amir Weiss | Senior VP & Chief Accounting Officer | S.O. | S.O. | 1977 |
| Ran Meir | Head of Investor Relations | S.O. | S.O. | S.O. |
| Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer | S.O. | S.O. | S.O. |
| Mr. David R. Mcavoy J.D. | Executive VP & Chief Legal Officer | S.O. | S.O. | 1963 |
| Ms. Vikki Conway | Acting Head of Global Human Resources | S.O. | S.O. | 1972 |
Description
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Teva Pharmaceutical Industries Limited en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 9; Société : 3; Droits des actionnaires : 5; Compensation : 4.
